Abstract: Disclosed herein are recombinant proteins and/or polypeptides comprising a Beclin 2 polypeptide and/or a targeting moiety and methods relating to treating, preventing, reducing, and/or inhibiting a cancer, metastasis, and/or a neurodegenerative disease comprising administering said recombinant protein or polypeptides.

Abstract: Disclosed herein are hydrogel devices and methods of making an use thereof. The devices can comprise: a continuous hydrogel matrix; a first chamber in the hydrogel matrix; and a second chamber in the hydrogel matrix; wherein the first chamber and the second chamber are each independently perfusable; wherein the first chamber is fluidly independent from the second chamber; wherein the first chamber is configured to be at least partially filled with adipose tissue; wherein the second chamber is configured to be at least partially filled with an oxygenated fluid; wherein the first chamber is defined by a first border; wherein the second chamber is defined by a second border; and wherein the first chamber and the second chamber are spaced apart from each other by an average distance of from 50 micrometers (microns, ?m) to 800 ?m as measured from the first border to the second border.

Abstract: An implantable device comprising a nanochanneled membrane is described. The device uses nanofluidics to control the delivery of diagnostic and/or therapeutic agents intratumorally. The devices can be used for chemotherapy, radiosensitization, immunomodulation, and imaging contrast.

Abstract: Devices and methods for controlling molecular transport are disclosed herein. The devices include a membrane having a plurality of nanochannels extending therethrough. The membrane has an inner electrically conductive layer and an outer dielectric layer. The outer dielectric layer creates an insulative barrier between the electrically conductive layer and the contents of the nanochannels. At least one electrical contact region is positioned on a surface of the membrane. The electrical contact region exposes the electrically conductive layer of the membrane for electrical coupling to external electronics. When the membrane is at a first voltage, molecules flow through the nanochannels at a first release rate. When the membrane is at a second voltage, charge accumulation within the nanochannels modulates the flow of molecules through the nanochannels to a second release rate that is different than the first release rate.

Abstract: Disclosed herein are devices for use in transplanting cells. The devices can include a housing defining a cavity; and a support structure separating the cavity into a cell chamber and a reservoir chamber, wherein the support structure comprises a membrane for fluid communication between the cell chamber and reservoir chamber. The cell chamber can define a first opening comprising a microstructure containing an array of micro-channels, each having a diameter to facilitate growth of vascular tissues; and an array of micro-reservoirs, each having a diameter to facilitate housing of cell aggregates individually. The membrane can define a surface area that is at least 50% of a total surface area of the support structure. Methods of treating a subject for a disease condition, such as diabetes, are also disclosed.

Abstract: The present disclosure provides solid drug formulations, in particular to stabilized formulations of phosphonamidate-containing drugs, as well as methods for loading drug delivery devices with solid formulations.

Abstract: Example neurostimulation induced medicine devices and methods of use are described herein. An example endotracheal device can include an elongate tubular member having a proximal end and a distal end, an inflatable cuff arranged between the proximal and distal ends of the elongate tubular member, and an electrode array disposed in proximity to an exterior surface of the inflatable cuff. The inflatable cuff can be configured to expand to contact a subject's tracheal wall. Additionally, the electrode array can include a plurality of flexible electrodes, where a set of the flexible electrodes anatomically align with a region of the subject's tracheal wall for selectively targeting vagus nerve activity.

Abstract: Provided herein are proton pump inhibitors that promote cellular senescence, methods of using the proton pump inhibitors to promote cellular senescence and compositions and kits comprising the proton pump inhibitors. Also provided are methods of screening for candidate agents that promote senescence or inhibit senescence.

Abstract: Provided herein are methods and devices for the detection, quantification, and/or monitoring of characteristics in samples. The disclosed methods and devices can be used, for example, to identify the presence and location of atrial fibrillation indicators with high spatial resolution. The disclosed methods and devices can even be used to identify the presence and location of atrial fibrillation indicators using non-simultaneously collected data.

Abstract: Compositions and methods for cross-regulation of type I interferon signaling pathways in pDCs for vaccine development are provided.

Abstract: Implementations of the present disclosure overcome the problems of the prior art by providing a brace for supporting a head of a wearer. The brace includes a head frame, a strap assembly and a cervical bar. The head frame is configured to grip the head of the wearer. The strap assembly is configured to extend along the wearers waist and back. The cervical bar has a first and second ends. The first end connects to and supports the head frame. The second end connects to and is supported by the strap assembly. Advantageously, the cervical bar has a stiffness sufficient to support the head and the head frame against head drop. The brace can do this without interfering with respiratory pathways.

Abstract: Compounds that target vascular endothelial growth factor receptors for therapy and imaging are disclosed. Methods for making the compounds and detecting or imaging cells expressing VEGFR using the compounds are also provided. In accordance with the purposes of the disclosed subject matter, as embodied and broadly described herein, disclosed are compounds, and methods of making and using the compounds. The disclosed compounds, in one aspect, are quinazoline compounds.

Abstract: Cells are magnetized and then grown in ring shaped 3D culture using a ring magnet. Contractility is measuring by tracking the size of the hole in the 3D cellular ring.

Abstract: Provided herein are compositions and kits comprising a therapeutic agent linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E. Also provided are methods of treating one or more symptoms of a disease or disorder characterized by expression of cathepsin E in a subject and methods of eliminating a cancer cell characterized by expression of cathepsin E using the provided compositions and kits. Further provided herein are methods of detecting the presence of a cancer cell or detecting a cathepsin E expressing cell using a photosensitizer linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E.

Abstract: Provided herein are polypeptides that are selectively cleaved by cathepsin E. Also provided are methods of detecting cathepsin E. The methods comprise contacting cathepsin E with the polypeptides provided herein and detecting fluorescence. Further provided are methods of diagnosing cancer or pre-cancerous conditions in a subject. Also provided herein is a multilayered nanoparticle or a composition comprising the multilayer nanoparticle, wherein the multilayered nanoparticle comprises a negatively charged nanoparticle core or capsule coated with alternating positive and negative layers. Optionally, the positive layer comprises a positively charged protease degradable polypeptide. Optionally, the negative layer comprises a negatively charged therapeutic agent or a therapeutic agent and a means for providing the agent with a negative charge. For example, optionally, the therapeutic agent is linked to a negatively charged polymer.

Abstract: Provided herein are compositions and kits comprising a therapeutic agent linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E. Also provided are methods of treating one or more symptoms of a disease or disorder characterized by expression of cathepsin E in a subject and methods of eliminating a cancer cell characterized by expression of cathepsin E using the provided compositions and kits. Further provided herein are methods of detecting the presence of a cancer cell or detecting a cathepsin E expressing cell using a photosensitizer linked to a cleavable substrate, wherein the cleavable substrate is capable of being cleaved by cathepsin E.

Abstract: Systems, methods and apparatuses for recording anatomic orientation and position.

Abstract: Provided herein are polypeptides that are selectively cleaved by cathepsin E. Also provided are methods of detecting cathepsin E. The methods comprise contacting cathepsin E with the polypeptides provided herein and detecting fluorescence. Further provided are methods of diagnosing cancer or pre-cancerous conditions in a subject. Also provided herein is a multilayered nanoparticle or a composition comprising the multilayer nanoparticle, wherein the multilayered nanoparticle comprises a negatively charged nanoparticle core or capsule coated with alternating positive and negative layers. Optionally, the positive layer comprises a positively charged protease degradable polypeptide. Optionally, the negative layer comprises a negatively charged therapeutic agent or a therapeutic agent and a means for providing the agent with a negative charge. For example, optionally, the therapeutic agent is linked to a negatively charged polymer.

Abstract: Systems, methods and apparatuses for recording anatomic orientation and position.

Abstract: Apparatus and method for filtering the electrocardiograph (ECG) signal of a patient of unwanted signals, such as contamination signals produced by the use of nuclear magnetic resonance imaging system or muscle artifact signals. In a preferred embodiment, variable filter (2) is used to filter an input ECG signal (1). The filtering characteristics applied to the ECG signal by variable filter (2) vary in response to the logical state of a synchronization signal indicating a patient's biophysical state which is input to variable filter (2) via line (3). In alternative embodiments, a QRS detector (22), a delay circuit (20), and a pulse stretcher (21) may be used to provide a synchronization signal. In another alternative embodiment, a microprocessor (24) with an input ECG signal and with input data is used to control the filtering of the ECG signal in synchronization with a patient's ECG signal.